Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 8/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | RHOA | P61586 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450403 | 1.00 | IDH1 (0.42) | IDH1PIM2SYKFYNRHOA | |
| SCHEMBL3448099 | 0.94 | MAOB (0.40) | PIM2SYKFYNRHOAMAOB | |
| SCHEMBL3448101 | 0.94 | MAOB (0.40) | PIM2SYKFYNRHOAMAOB | |
| SCHEMBL13312476 | 0.93 | THRB (0.37) | IDH1PIM2SYKNPC1RAB9A | |
| SCHEMBL3449514 | 0.91 | SYK (0.42) | SYKNPC1MAPT | |
| SCHEMBL3449517 | 0.91 | SYK (0.42) | SYKNPC1MAPT | |
| SCHEMBL3448610 | 0.89 | MAPK3 (0.40) | PIM2SYK | |
| SCHEMBL3448626 | 0.89 | MAPK3 (0.40) | PIM2SYK | |
| SCHEMBL3451242 | 0.89 | SYK (0.41) | PIM2SYKRHOANPC1RAB9A | |
| SCHEMBL3451237 | 0.89 | SYK (0.41) | PIM2SYKRHOANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | IDH1 718/4885PIM2 3060/4885SYK 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.